SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea · Delayed Price · Currency is KRW

102,900

-3,700 (-3.47%)

At close: Mar 6, 2026

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
New Pharmaceutical Business	547.60B	354.89B	246.18B	418.64B	26.00B
New Pharmaceutical Business Growth	54.30%	44.16%	-41.20%	1510.23%	-79.01%
Total	547.60B	354.89B	246.18B	418.64B	26.00B
Total Growth	54.30%	44.16%	-41.20%	1510.23%	-79.01%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Korea	474.43B	310.70B	214.94B	455.25B	-
Korea Growth	52.69%	44.55%	-52.79%	-	-
United States of America	667.82B	508.89B	388.21B	267.22B	12.06B
United States of America Growth	31.23%	31.09%	45.28%	2114.91%	-87.78%
Unallocated	-594.66B	-464.70B	-356.97B	-303.83B	-
Japan	-	-	-	-	7.55B
Netherlands	-	-	-	-	924.13M
Ireland	-	-	-	-	5.46B
Total	547.60B	354.89B	246.18B	418.64B	26.00B
Total Growth	54.30%	44.16%	-41.20%	1510.23%	-79.01%

Source: S&P Global Market Intelligence.